|
29 May 2021 |
Humanigen Submits Application to FDA for Emergency Use Authorization for Lenzilumab in COVID-19
|
|
29 May 2021 |
Ipsen Confirms U.S. FDA Accepts New Drug Application for Palovarotene as the First Potential Treatment Worldwide for Fibrodysplasia Ossificans Progressiva (FOP)
|
|
29 May 2021 |
Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program
|
|
29 May 2021 |
Novo Nordisk resubmits once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes for US regulatory approval
|
|
29 May 2021 |
FDA Approves LUMAKRAS™ (Sotorasib), The First And Only Targeted Treatment For Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
|
|
28 May 2021 |
CStone Announces the First-in-Class Registrational Clinical Trial of Sugemalimab Met its Primary Endpoint in Stage III NSCLC and Plans to Submit a New Drug Application
|
|
28 May 2021 |
Tagrisso approved in the EU for the adjuvant treatment of patients with early-stage EGFR-mutated lung cancer
|
|
28 May 2021 |
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Zeposia® (ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis
|
|
27 May 2021 |
Kymera Therapeutics Presents New Data Demonstrating Proof-of-Degradation Using Novel Tissue-Restricted E3 Ligase
|
|
27 May 2021 |
Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids
|
|
27 May 2021 |
Oncorus Announces Nomination of its First IV-Administered Synthetic Viral RNA (vRNA) Immunotherapy Product Candidates, ONCR-021 and ONCR-788
|
|
27 May 2021 |
eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement to Create Publicly Listed, Next-Generation Oncology Company Developing New Class of Cancer Therapies
|
|
27 May 2021 |
Cellphire Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Thrombosomes in Bleeding Thrombocytopenic Patients
|
|
27 May 2021 |
AGT Announces Progress with HIV Cure Program, Phase 1 Clinical Trial
|
|
27 May 2021 |
Daewoong, first-in-class PRS-inhibitor for Idiopathic Pulmonary Fibrosis(IPF) shows promising result in early stage clinical test
|
|
27 May 2021 |
Concert Pharmaceuticals Initiates THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
|
|
27 May 2021 |
Dicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for LY3819469
|
|
27 May 2021 |
Horizon Therapeutics plc Initiates ADVANCE Trial Evaluating KRYSTEXXA® (pegloticase injection) with Methotrexate for People Who Previously Developed Anti-Drug Antibodies on KRYSTEXXA Monotherapy
|
|
27 May 2021 |
Zydus seeks DCGI approval to undertake clinical trials for monoclonal antibodies cocktail that can neutralise COVID infection
|
|
27 May 2021 |
GSK and Vir Biotechnology announce sotrovimab (VIR-7831) receives Emergency Use Authorization from the US FDA for treatment of mild-to-moderate COVID-19 in high-risk adults and paediatric patients
|
